Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?

Eva M. M. Strijbis*, Anne Kerbrat, John R. Corboy

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademic

Original languageEnglish
Pages (from-to)E1-E2
JournalJAMA Neurology
Early online date2021
DOIs
Publication statusE-pub ahead of print - 2021

Cite this